Antibody Neutralization of CXCL10in VivoIs Dependent on Binding to Free and Not Endothelial-bound Chemokine
出版年份 2017 全文链接
标题
Antibody Neutralization of CXCL10in VivoIs Dependent on Binding to Free and Not Endothelial-bound Chemokine
作者
关键词
-
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 292, Issue 10, Pages 4185-4197
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2017-01-31
DOI
10.1074/jbc.m116.745877
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models
- (2015) Stanley Lasch et al. DIABETES
- “Chemokine receptors as therapeutic targets: Why aren’t there more drugs?”
- (2015) Roberto Solari et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- De novoisolation of antibodies with pH-dependent binding properties
- (2015) Pauline Bonvin et al. mAbs
- CCR4 and its ligands: from bench to bedside
- (2014) O. Yoshie et al. INTERNATIONAL IMMUNOLOGY
- CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis
- (2014) Yaniv Zohar et al. JOURNAL OF CLINICAL INVESTIGATION
- Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment
- (2014) Naofumi Mukaida et al. MEDIATORS OF INFLAMMATION
- CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
- (2014) M. Rashighi et al. Science Translational Medicine
- Biased and G Protein-Independent Signaling of Chemokine Receptors
- (2014) Anne Steen et al. Frontiers in Immunology
- Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking
- (2013) Iain Comerford et al. BRITISH JOURNAL OF HAEMATOLOGY
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study
- (2013) Lloyd Mayer et al. GUT
- Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data
- (2013) Gerald J. Fetterly et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients
- (2013) M. Weber et al. SCIENCE
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells
- (2012) Tajie H. Harris et al. NATURE
- A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis
- (2011) Michael Yellin et al. ARTHRITIS AND RHEUMATISM
- Chemokine oligomerization and interactions with receptors and glycosaminoglycans: The role of structural dynamics in function
- (2011) C.L. Salanga et al. EXPERIMENTAL CELL RESEARCH
- Targeting chemokine receptors in chronic inflammatory diseases: An extensive review
- (2011) Pim J. Koelink et al. PHARMACOLOGY & THERAPEUTICS
- CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation
- (2010) Edith Hintermann et al. JOURNAL OF AUTOIMMUNITY
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- T1145 A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal Antibody, in Healthy Subjects
- (2008) Michael Yellin et al. GASTROENTEROLOGY
- Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria
- (2008) G. S. V. Campanella et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started